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Biomarkers for the Early Detection of Hepatocellular Carci-
noma. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di
Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag
JL; HALT-C Trial Group. Reprinted from Gastroenterology 2009 Oct
20 [Epub ahead of print], with permission from Elsevier.
Abstract: Background & Aims. The outcome of patients with hepa-
tocellular carcinoma (HCC) remains poor because of late diagno-
sis. The aim of this study was to compare the accuracy of alpha-
fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) in
the early diagnosis of HCC. Methods: Among 1031 patients ran-
domized in the Hepatitis C Antiviral Long-term Treatment
Against Cirrhosis (HALT-C) Trial, a nested case-control study of
39 HCC cases (24 early stage) and 77 matched controls was con-
ducted to compare the performance of AFP and DCP. Testing was
performed on sera from 12 months prior (month-12) to the time
of HCC diagnosis (month 0). Results: The sensitivity and speciﬁc-
ity of DCP at month 0 was 74% and 86%, respectively, at a cut-off
of 40 mAU/ml and 43% and 100%, respectively, at a cutoff of
150 mAU/ml. The sensitivity and speciﬁcity of AFP at month 0
was 61% and 81% at a cutoff of 20 ng/ml and 22% and 100% at a
cutoff of 200 ng/ml. At month-12, the sensitivity and speciﬁcity
at the low cutoff was 43% and 94%, respectively, for DCP and
47% and 75%, respectively, for AFP. Combining both markers
increased the sensitivity to 91% at month 0 and 73% at month
12, but the speciﬁcity decreased to 74% and 71%, respectively.
Diagnosis of early HCC was triggered by surveillance ultrasound
in 14, doubling of AFP in 5, and combination of tests in 5 patients.
Conclusions: Biomarkers are needed to complement ultrasound in
the detection of early HCC, but neither DCP nor AFP is optimal.
 2010 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
The HALT-C study [1] is like the ‘‘gift that keeps on giving”, pro-
viding data for analysis after analysis. Recently the HALT-C team
have addressed the issue of using alphafetoprotein and des-
gamma carboxyprothombin for surveillance for HCC [2]. They
analysed the serum concentrations of these markers at the time
of diagnosis of HCC and 12 months prior to the diagnosis. TheJournal of Hepatology 20
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E-mail address: morris.sherman@uhn.on.caover the 12 months prior to diagnosis. At diagnosis the sensitivity
of a DCP measurement was 74% if the assay cut-off was 40 mAU/
ml, and 43% at a cut-off of 150 mAU/ml. In contrast, 12 months
prior to the diagnosis of HCC (when the HCC must have been
present) the sensitivity was 43% at a cut-off of 40 mAU/mL and
3% at a cut-off of 150 mAU/ml. The results for AFP were similar,
poor sensitivity at 12 months prior to the diagnosis and some-
what better sensitivity at the time of diagnosis. At the time of
diagnosis, the sensitivity of AFP at a cut-off of 20 ng/ml was
61%, and at a cut-off of 200 ng/ml the sensitivity at diagnosis
was 22%. At 12 months prior to diagnosis, the sensitivity of AFP
at the 20 ng/ml cut-off was 47%. The authors conclude that nei-
ther AFP nor DCP are adequate for HCC surveillance.
These results should be considered together with other results
recently published (‘‘theMarrero study”) inwhich the value of DCP
was evaluated as a surveillance test [3]. The authors concluded that
DCP was a sensitive marker for the diagnosis of small HCC, and
since HCC smaller than 2 cm should be the target of surveillance;
ergoDCPwasagood test forHCCsurveillance.However, evaluating
a test for HCC in the presence of knownHCC, even small HCC, is not
the same as using the test in a surveillance population. Because the
study population was selected on the basis of having HCC, rather
thanon thebasis of having for example cirrhosis, the results cannot
necessarily be extrapolated to a cirrhotic population without
knownHCC, such as the one studied by Lok and colleagues [2]. Fur-
thermore, in a population with known HCC, further bias may be
introduced by the use of AFP to make the initial diagnosis. Even
with these proviso’s the Marrero study [3] found that neither AFP
norDCPwere very gooddiagnosticmarkers forHCC. Thus, Dr. Lok’s
study [2] provides a higher level of evidence than the earlier study.
These results are another nail in the cofﬁn of serological sur-
veillance for HCC in general and AFP surveillance in particular.
Despite an obituary for AFP as a surveillance test written in
2001 [4], AFP surveillance for HCC is proving surprisingly hard
to kill. More recently, an editorial accompanying the earlier study
came to the same conclusion; AFP surveillance is ‘‘dead” [5]. The
continued use of AFP is in part due to the fact that an elevated
AFP is a risk factor for HCC. Patients with cirrhosis who have a
persistently elevated AFP are at higher risk for HCC than similar
patients in whom the AFP is not elevated. When patients undergo
regular AFP surveillance and an elevated value is found this trig-
gers further investigations. HCC is more likely to be discovered,
simply because HCC will be more prevalent in a population with
an elevated AFP than in population with a normal AFP. This does
not make AFP a good surveillance test. The AFP is elevated10 vol. 52 j 614–615
JOURNAL OF HEPATOLOGY
because of the chronic underlying liver disease, rather than the
HCC. There is good data on the lack of sensitivity of AFP for
HCC surveillance [6]. There are too many false-positives, and
too many false-negatives to make this a useful test.
Is DCP any better? DCP is a better serological diagnostic mar-
ker for HCC than AFP [3]. It is more likely to be diagnostically ele-
vated in patients with HCC, although a sensitivity of 74% at the
time of diagnosis found in the Marrero study [3] is not ideal.
Unfortunately, both AFP and DCP are also risk factors for
advanced disease, i.e., micro- or macrovascular invasion and/or
portal vein thrombosis [7,8]. They cannot therefore also be
good markers for surveillance, which aims to catch early stage
disease.
For HCC surveillance to be effective it should detect HCC at a
stage when cure is highly likely. Currently only regular ultraso-
nography will do this reliably. In countries where surveillance
is assiduously carried out, more than 60% of HCC’s are diagnosed
smaller than 3 cm. Patients at risk for HCC should undergo ultra-
sound surveillance at 6 monthly intervals. The AASLD guidelines
to help evaluate newly discovered lesions on HCC surveillance [9]
have been validated [10] and should be used.References
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